-
Signature
-
/s/ Yoshihiro Nakagawa, Global General Counsel of Takeda Pharmaceutical Company Limited
-
Stock symbol
-
HLVX
-
Transactions as of
-
May 3, 2022
-
Transactions value $
-
$0
-
Form type
-
3/A - Amendment
-
Date filed
-
5/9/2022, 06:10 AM
-
Date Of Original Report
-
Apr 29, 2022
Transactions Table
Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
holding |
HLVX |
Common Stock |
|
|
|
|
|
841K |
May 3, 2022 |
See Explanation of Responses |
F1 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
holding |
HLVX |
Warrant (Right to Buy) |
|
|
|
|
|
|
May 3, 2022 |
Common Stock |
5.88M |
$0.00 |
See Explanation of Responses |
F1, F2 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
Remarks:
This amendment is being filed to correct the reporting person's initial Form 3 filed on April 29, 2022 to reflect (a) a 1.681-for-1 forward stock split of the Issuer's common stock effected on April 22, 2022 which resulted in (i) an increase in the reporting persons ownership of (x) common stock from 500,000 to 840,500 and (y) warrants from 3,500,000 to 5,883,500 and (ii) the exercise price of the warrants changing from $0.0001 to $0.0000595 and (b) a correction to the date on which the Warrant is exercisable, from April 28, 2022 to May 3, 2022, the latter reflecting the date on which the Issuer's initial public offering was consummated and the date on which the Warrant to purchase 5,883,500 shares of Common Stock became exercisable.